Početna › Leukemija
Kliničke studije za Leukemija koje traže sudionike u SAD-u
102 studija za Leukemija traži sudionike na lokacijama širom Sjedinjenih Američkih Država.
Gradovi s najviše studija
- Houston, TX28 studija
- Boston, MA25 studija
- New York City, NY19 studija
- Los Angeles, CA16 studija
- Chicago, IL16 studija
- Durham, NC13 studija
- Baldwin Park, CA12 studija
- Columbus, OH12 studija
- Nashville, TN12 studija
- Philadelphia, PA12 studija
- Milwaukee, WI11 studija
- Atlanta, GA11 studija
- Seattle, WA11 studija
- Birmingham, AL10 studija
- Aurora, CO10 studija
- Edison, NJ9 studija
- Mountain View, CA9 studija
- Miami, FL9 studija
- Cincinnati, OH9 studija
- Portland, OR8 studija
- Queens, NY8 studija
- Dallas, TX8 studija
- New Haven, CT8 studija
- Buffalo, NY7 studija
- Denver, CO7 studija
- Orange, CA7 studija
- Washington, DC7 studija
- Tampa, FL7 studija
- Clifton, NJ7 studija
- Cedar Rapids, IA6 studija
- Omaha, NE6 studija
- Baltimore, MD5 studija
- Charlottesville, VA5 studija
- Ann Arbor, MI5 studija
- Memphis, TN5 studija
- Rochester, MN5 studija
- San Diego, CA5 studija
- Cleveland, OH5 studija
- Charlotte, NC5 studija
- Rochester, NY4 studija
Po državama
- Alabama10 studija
- Arizona7 studija
- Colorado15 studija
- Connecticut11 studija
- Florida17 studija
- Georgia13 studija
- Illinois17 studija
- Indiana4 studija
- Iowa7 studija
- Kalifornija28 studija
- Kansas5 studija
- Kentucky6 studija
- Louisiana3 studija
- Maine3 studija
- Maryland11 studija
- Massachusetts28 studija
- Michigan8 studija
- Minnesota9 studija
- Missouri6 studija
- Nebraska6 studija
- New Jersey15 studija
- New Mexico3 studija
- New York26 studija
- North Carolina20 studija
- Ohio26 studija
- Oklahoma4 studija
- Oregon9 studija
- Pennsylvania15 studija
- Rhode Island4 studija
- South Carolina6 studija
- Tennessee14 studija
- Texas31 studija
- Utah4 studija
- Vermont4 studija
- Virginia7 studija
- Washington11 studija
- Wisconsin13 studija
Nedavno ažurirane studije
Službeni tekst studije (engleski)
Rutgers University Study of the Genetics of Blood Cancers
U tijeku regrutacijaOpažajna studijaZdravi dobrovoljci dobrodošli
Od 18 do 110 godina · Oba spola · Ažurirano 1. lis 2026. · NCT07714044Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
U tijeku regrutacijaOpažajna studija
Od 0 do 38 godina · Oba spola · Ažurirano 1. lis 2026. · NCT06131801Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)
U tijeku regrutacijaOpažajna studija
Od 18 do 110 godina · Oba spola · Ažurirano 28. ruj 2026. · NCT00923507Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
U tijeku regrutacijaFaza 3
Od 18 do 71 godina · Oba spola · Ažurirano 23. ruj 2026. · NCT07504458Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia
U tijeku regrutacijaFaza 2
Od 1 do 25 godina · Oba spola · Ažurirano 23. ruj 2026. · NCT05645718Natural History Study of GATA2 Deficiency and Related Disorders
U tijeku regrutacijaOpažajna studijaZdravi dobrovoljci dobrodošli
Od 2 do 100 godina · Oba spola · Ažurirano 22. ruj 2026. · NCT01905826A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
U tijeku regrutacijaFaza 1/2
30 Days · Oba spola · Ažurirano 16. ruj 2026. · NCT04065399Chimeric Antigen Receptor Treatment Targeting CD70 (SEVENTY)
U tijeku regrutacijaFaza 1
Do 75 godina · Oba spola · Ažurirano 16. ruj 2026. · NCT06345027Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 16. ruj 2026. · NCT06824168A Prospective Trial of Dalbavancin-Based Prophylaxis in Children and Adolescents With High-Risk Leukemia
U tijeku regrutacijaFaza 1
Do 25 godina · Oba spola · Ažurirano 15. ruj 2026. · NCT06810583(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 15. ruj 2026. · NCT04996875A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes
U tijeku regrutacijaFaza 2
Od 12 godina i više · Oba spola · Ažurirano 11. ruj 2026. · NCT06229912Tools for Reducing Inequity in Acute Leukemia (TRIAL): Beta Testing
U tijeku regrutacija
Od 18 godina i više · Oba spola · Ažurirano 9. ruj 2026. · NCT06907797Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
U tijeku regrutacijaFaza 3
Od 18 do 18 godina · Oba spola · Ažurirano 8. ruj 2026. · NCT07509151Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 2. ruj 2026. · NCT07249346Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
U tijeku regrutacijaFaza 2
Od 1 do 18 godina · Oba spola · Ažurirano 2. ruj 2026. · NCT07354074Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies
U tijeku regrutacijaFaza 1
Od 1 do 25 godina · Oba spola · Ažurirano 1. ruj 2026. · NCT06408194First-in-human Study of a New Treatment (4A10) for Patients With Relapsed or Hard-to-treat Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma, Focused on Safety and How the Drug Behaves in the Body and Early Signs of Effect.
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 1. ruj 2026. · NCT07586618Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies Who Receive CAR T-cell Therapy
U tijeku regrutacijaOpažajna studijaZdravi dobrovoljci dobrodošli
Od 5 godina i više · Oba spola · Ažurirano 31. kol 2026. · NCT05237986CIML NK Cells With Venetoclax for AML
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 28. kol 2026. · NCT06152809Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 28. kol 2026. · NCT07284433Assessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid Leukemia
U tijeku regrutacijaFaza 1
Od 18 do 90 godina · Oba spola · Ažurirano 26. kol 2026. · NCT07439211Study of QUAIL-100 in Pediatric and Young Adult Participants With High-Risk Hematologic Malignancies Who Have Received a Hematopoietic Stem Cell Transplantation
U tijeku regrutacijaFaza 1
18 Months – 39 Years · Oba spola · Ažurirano 21. kol 2026. · NCT07573111Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 20. kol 2026. · NCT07007312Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 20. kol 2026. · NCT06001788Iz ClinicalTrials.gov, podaci preuzeti 4. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.